Search

Your search keyword '"Li, Yu-Ping"' showing total 623 results
Start Over Author "Li, Yu-Ping"
623 results on '"Li, Yu-Ping"'

156. A novel LC-MS/MS method for mepivacaine determination and pharmacokinetic study in a single-dose two-period crossover in healthy subjects.

Author

Duan, Ruo-Wang, Song, Jiong, Li, Yu-Ping, and Xing, Chun-Gen

Subjects
LOCAL anesthetics, DRUG dosage, PHARMACOKINETICS, LIQUID chromatography-mass spectrometry, BLOOD plasma
Abstract

The objective of this work was to develop a simple, selective, and sensitive LC–MS/MS method for the quantitation of the mepivacaine in Chinese biological matrix. The calibration curve of mepivacaine ranged from 0.5 to 2000 ng/mL with the lower limit of quantitation being 0.5 ng/mL. This sensitivity was high enough to describe the profile of blood mepivacaine level versus time. Thereby it was very desirable for the pharmacokinetic study because of its high sensitivity and accuracy. The study used a single-dose two-period crossover design principle. For the pharmacokinetic analysis of plasma, the mean (SD) values obtained were as follows: t1/2, 1.63 (0.43) h;Cmax, 435.3 (67.4) ng/ml;AUC0-t, 1546.9 (339.7) ng/ml·h;AUC0-∞, 1982.3 (421.4) ng/ml·h;Tmax, 0.62 (0.31) h. The validated method has been successfully applied to assess the pharmacokinetic study of mepivacaine after a single administration to Chinese volunteers. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

158. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

Author

Xi-Xi Lai, Li Yu-Ping, Han Yang, and Ren-Ai Xu

Subjects
safety, 0301 basic medicine, Oncology, medicine.medical_specialty, Bevacizumab, medicine.drug_class, Monoclonal antibody, OncoTargets and Therapy, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Pharmacology (medical), Lung cancer, Adverse effect, Original Research, business.industry, toxicities, angiogenesis inhibitors, medicine.disease, respiratory tract diseases, meta-analysis, Vascular endothelial growth factor, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Meta-analysis, non-small-cell lung carcinoma, Non small cell, business, medicine.drug
Abstract

Xi-Xi Lai, Ren-Ai Xu, Yu-Ping Li, Han Yang Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China Background: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor ligand, has shown survival benefits in the treatment of many types of malignant tumors, including non-small-cell lung cancer (NSCLC). We conducted this systematic review and meta-analysis to investigate the risk of the most clinically relevant adverse events related to bevacizumab in advanced NSCLC.Methods: Databases from PubMed, Web of Science, and Cochrane Library up to August 2015, were searched to identify relevant studies. We included prospective randomized controlled Phase II/III clinical trials that compared therapy with or without bevacizumab for advanced NSCLC. Summary relative risk (RR) and 95% confidence intervals were calculated using random effects or fixed effects according to the heterogeneity among included trials.Results: A total of 3,745 patients from nine clinical trials were included in the meta-analysis. Summary RRs showed a statistically significant bevacizumab-associated increased risk in three of the adverse outcomes studied: proteinuria (RR =7.55), hypertension (RR =5.34), and hemorrhagic events (RR =2.61). No statistically significant differences were found for gastrointestinal perforation (P=0.60), arterial and venous thromboembolic events (P=0.35 and P=0.92, respectively), or fatal events (P=0.29).Conclusion: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. Keywords: toxicities, angiogenesis inhibitors, non-small-cell lung carcinoma, meta-analysis, safety

Published
2016

159. Dynamic Change of Ecological Footprint in Xingtai City in the Years 2003-2009

Author

Chen, Ji-Bing and Li, Yu-Ping

Subjects
China, Sustainable development, Ecological footprint, Agribusiness, Ecological carrying capacity, Xingtai City
Abstract

Quantitative estimation of the ecological footprint in Xingtai City in the years 2003-2009 is carried out by using the Ecological Footprint Model and the Time Series. Result shows that the per capita ecological footprint demand increases in Xingtai City from the year 2003 to 2009; and land use for energy shows a significant increase, accounting for the maximum proportion in per capita ecological footprint demand. Per capita ecological footprint supply gradually decreases. Ecological supply provided by cultivated land occupies the greatest proportion in the supply of per capita ecological carrying capacity, which is the main factor determining the supply of ecological carrying capacity in Xingtai City. In the years 2003-2009, ecological footprint of Xingtai City is at the state of ecological deficit. This indicates that the economic and social development of Xingtai City is based on the over-exploitation of resources, especially the cultivated land and energy land. Thus, the development mode of Xingtai City has already been in a state of unsustainable development. Based on this, corresponding countermeasures are put forward for the sustainable development in future, so as to implement the healthy control of the sustainable development in Xingtai City, China.

Published
2011
Full Text
View/download PDF

170. Prediction of the Cultivated Land Demand Based on Logistic Equation - A Case of Zhejiang Province, China

Author

Qiao, Ruibo, Li, Yu-Ping, and Cai, Yunlong

Subjects
China, Cultivated land demand, Zhejiang Province, Prediction, Logistic Equation, Land Economics/Use, Research Methods/ Statistical Methods
Abstract

Regional situation of Zhejiang Province and connotation of Logistic Equation are introduced. According to the relevant statistical data from 1978 to 2006, dynamic change and its driving forces of cultivated land area in Zhejiang Province are analyzed. ① Since the year 1978, cultivated land area has shown a significant fluctuant decreasing trend in Zhejiang Province, China. ② Cultivated land at the two stages of 1984-1988 and 1990-1995 decreases sharply. Large area of cultivated land is occupied by non-agricultural construction. ③ Economic development, population growth and agricultural scientific and technological development are the main driving forces. Contradiction between land and human beings becomes more acute; and the load of cultivated land becomes increasingly heavy. ④ Cumulative reduction area of cultivated land changes with time, showing a "S"-shaped curve and according with the Logistic Equation. Change of cultivated land of Jiangsu Province in future is forecasted by Logistic Equation. Result shows that the cumulative reduction area of cultivated land will stop increasing until the year 2020 with the total reduction area of 90.91 thousand hectares. Cultivated area of Zhejiang Province will either be stable at the level of 1498.24 thousand hectares or will fluctuate around it. With the development of industrial structure, encroachment of urbanization and industrialization on cultivated land is not ever-increasing, but will tend to stop at a certain stage. Overall consideration on land use demand for food safety and for urbanization and industrialization may become possible with the advancement of technology and the increase of land inputs.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results